Skip to main content
Signal8

NORTHWEST BIOTHERAPEUTICS INC (NWBO) Form 10-Q — Nov 13, 2026

$NWBOForm 10-QFiled Nov 13, 2026, 4:36 PM ET0001104659-26-127129Original filing

Northwest Biotherapeutics reported a Q3 2026 net loss of $28.8 million and a nine-month net loss of $41.1 million, improved from $61.6 million a year earlier, on revenues of just $0.9 million for the quarter. Cash and equivalents fell to only $0.725 million from $3.0 million at year-end 2025, while total liabilities stand at $122.4 million against a stockholders' deficit of $56.7 million. The company disclosed substantial doubt about its ability to continue as a going concern for at least one year from the filing date, stating its existing liquidity is not sufficient to fund operations until it reaches significant revenues.

Key figures

Total Debt
64511000
Cash Position
725000
Shares Outstanding
1811970770
Q3 revenue
883000
Total liabilities
122441000
Nine month g and a
19843000
Nine month r and d
14785000
Nine month revenue
2184000
Subsequent event loan
5505000
Standby equity facility
50000000
Debt extinguishment loss nine months
9980000
Shares issued for debt conversion nine months
117.4 million shares for $21.5 million of convertible notes at weighted average $0.18 per share

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    NORTHWEST BIOTHERAPEUTICS INC (NWBO) Form 10-Q — Nov 13, 2026: AI Analysis | Signal8